Compare GSK plc (GSK) vs Honeywell International Inc (HON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Honeywell International Inc — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while Honeywell International Inc trades at $207.77 (market cap $65.48B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Honeywell International Inc for 91 Days on average.
| GSK | HON | |
|---|---|---|
Market Cap | $91.88B | $65.48B |
Volume | 7,730,529 | 2,047,782 |
Sector | Health | Industrials |
52-Week High | $61.18 | $248.79 |
52-Week Low | $43.24 | $188.14 |
Typical Hold Time | 93 Days | 91 Days |
Enterprise Value | $111.88B | $90.27B |
Dividend Yield | 3.9% | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Honeywell International (HON) trades at $207.73, down 0.18% with a bearish technical signal despite strong fundamentals. The company shows robust profitability with 21.58% net margin and 47.43% ROE, trading at attractive valuations (P/E 7.94, EV/EBITDA 6.72). Recent Q2 2026 earnings beat expectations, and the company secured a $300 million refinery project with Dangote. Analyst consensus remains strongly bullish with 67% buy ratings and $259.25 price target, representing 25% upside potential.
HON presents a compelling value opportunity with strong fundamentals and positive analyst sentiment, though technical indicators suggest near-term caution. The company's post-spin focus on automation and recent contract wins provide growth catalysts, while rising debt levels and cyclical industrial exposure pose moderate risks. Wall Street optimism contrasts with current bearish technical positioning, creating potential for convergence if fundamentals drive price action.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →
